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Abstract
Coronary artery disease (CAD) is the leading cause of mortality in patients with chronic kidney disease (CKD). Patients with CKD who
undergo percutaneous coronary intervention (PCI) may have more ischemic events than patients without CKD. The aim of our study
was to determine the incidence of periprocedural myocardial injury (PMI) after elective stent implantation in patients with CKD using
the Third Joint ESC/ACCF/AHA/WHF PMI deﬁnition.
In a single center prospective cohort study, we enrolled 344 consecutive patients who underwent elective PCI in a period of 39
months. Serum troponin I (cTnI) concentrations were measured at baseline and at 8 and 16hours after PCI. Periprocedural increase
of cTnI, according to the most recent PMI deﬁnition, was used to deﬁne both the presence and intensity of PMI. Patients were further
stratiﬁed according to the estimated glomerular ﬁltration rate (eGFR) using 4 variable Modiﬁcation of Diet in Renal Disease (MDRD)
equation: control group with eGFR >90mL/min/1.73 m2 and the CKD group with eGFR<90mL/min/1.73 m2, with further
subdivision according to the CKD stage.
We found no signiﬁcant difference in the incidence as well as intensity of the PMI in the control (>90mL/min/1.73 m2) and the CKD
group (<90mL/min/1.73 m2) both 8 and 16hours after PCI. When the CKD patients were further subdivided according to their CKD
stage, there was again no difference in the intensity or incidence of PMI compared to the control group. Further analyses of our data
showed angina pectoris CCS IV, bare metal stent (BMS) implantation, and treatment with angiotensin-converting enzyme inhibitors
(ACEI) as independent predictors of PMI. Furthermore, the presence of hypertension was inversely related to the occurrence of PMI.
Applying the new guidelines for PMI and using the eGFR equation most suitable for our patients, we found no association between
PMI and CKD. Further analyses showed other factors that could potentially inﬂuence the occurrence of PMI.
Abbreviations: ACCF/AHA = American College of Cardiology Foundation/American Heart Association, ACEI = angiotensin-
converting enzyme inhibitor, ARB = angiotensin II receptor blocker, BMI = body mass index, BMS = bare metal stent, CABG =
coronary artery bypass grafting, CAD = coronary artery disease, CCS = Canadian Cardiovascular Society, CK-MB = creatine kinase
MB fraction, CKD = chronic kidney disease, CRP = C-reactive protein, cTnI = cardiac troponin I, DES = drug-eluting stent, eGFR =
estimated glomerular ﬁltration rate, ESC= European Society of Cardiology, ESRD= end-stage renal disease, MACE=major adverse
cardiovascular events, MDRD = Modiﬁcation of Diet in Renal Disease, MI = myocardial infarction, PCI = percutaneous coronary
intervention, PMI = periprocedural myocardial injury, QCA = quantitative coronary angiography, ST = stent thrombosis, TIMI =
thrombolysis in myocardial infarction, TVR = target vessel revascularization, URL = upper reference limit, WHR = World Heart
Federation.
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11. Introduction
Coronary artery disease (CAD) is the leading cause of death in
patients with chronic kidney disease (CKD).[1] Dialysis patients
experience a mortality rate after myocardial infarction that is up
to 15 times higher than in patients with normal renal function.
Mortality at 1 year after myocardial infarction can reach as high
as 59% in the dialysis population.[2] The excess cardiovascular
risk with CKD is explained by higher prevalence of well-
established cardiovascular risk factors such as hypertension,
diabetes mellitus, dyslipidaemia, and uremia, which all promote
rapid progression of CAD.[3]
Patients with CKD have been reported to have elevated risk of
adverse clinical outcomes after coronary revascularization,
including higher incidence of myocardial infarction, as compared
to non-CKD patients.[4] In a largest study to date examining risk
factors for in-hospital mortality following PCI in 25018 patients,
Jerkic et al. Medicine (2016) 95:45 MedicineCKD, especially end-stage renal disease (ESRD), was found to be
independently associated with increased in-hospital all-cause
mortality. Independent risk factors in patients with ESRD
included myocardial infarction within 72 hours, while emergency
PCI was associated with increased risk of death in patients with
moderate CKD.[5]
Although the PCI may be a high-risk procedure in CKD, PCI
was associated with lower risk of death in end-stage renal disease
patients, compared with no revascularization.[6] Thus, the
presence of kidney disease or dependence on dialysis should
not be the barrier to PCI revascularization in patients with acute
coronary syndrome.
However, despite prevalence of reports on adverse association
of CKD with PCI outcome in the acute setting (i.e. for acute
coronary syndrome), there is still a shortage of studies addressing
effect of CKD burden on early outcomes of elective PCI.
Therefore, our study was designed to test the hypothesis that
presence of CKD and its burden (CKD grade) would be
associated with increased risk of PMI in elective PCI patients.2. Methods
This study prospectively included 344 consecutive patients with
stable angina pectoris who underwent an elective PCI at Merkur
University Hospital, Zagreb, Croatia. Enrollment period was 39
months, that is, between March 2012 and June 2015. This study
was approved by the Merkur Hospital ethics committee and all
patients provided informed consent. The primary endpoint was
incidence of PMI, depending on eGFR. All patients had stable
angina pectoris with documented inducible myocardial ischemia.
Stable patients were deﬁned as those with no recent deterioration
of pain in the previous 2 months or without rest angina in the
previous 48hours. Further criteria for inclusion were that the PCI
procedure was successful and an optimal ﬁnal result was
obtained, that is, a thrombolysis in myocardial infarction (TIMI)
ﬂow grade 3 in the treated vessel with a residual stenosis < 20%
by quantitative coronary angiography (QCA).
The exclusion criteria were: age <18, acute coronary
syndrome, acute kidney injury, multivessel stenting in a single
procedure, major (>1.5mm) side branch occlusion, chronic total
occlusion, major hemorrhage within 4 weeks or contraindication
to the use dual antiplatelet therapy, unsuccessful procedures, and
target lesion in saphenous graft. All patients received a dual
antiplatelet therapy with aspirin 100mg/day and clopidogrel 75
mg/day for 5 days before elective PCI. Immediately before PCI
procedures, a bolus of unfractionated heparin according to a
standardized protocol was administered. PCI procedures were
performed using either of 2 types of low osmolar contrast media,
iodixanol, or ioversol.
Serum TnI levels were measured using a chemiluminescent
microparticle immunoassay technology (CMIA) on the ARCHI-
TECT I System with STAT protocol capability (AbbottTable 1
Deﬁnition of high and low degree periprocedural myocardial injury.
PMI Baseline cTnI (ng/mL)
No PMI <URL
PMI low degree <URL
PMI high degree <URL
PMI low degree >URL (stable or falling)
PMI high degree >URL (stable or falling)
cTnI= cardiac troponin I, PMI=periprocedural myocardial injury, URL=upper reference limit (0.04ng/m
2Laboratories, Abbott Park, IL 60064). All blood samples have
been tested with the same reagents kit (ARCHITECT STAT
Troponin-I Reagent Kit).
Blood samples were collected immediately before PCI and at 8
and 16hours after PCI.
The upper reference limit (URL) of serum cTnI was 0.04ng/
mL. PMI was deﬁned as an increase in cTnI at 8 or 16hours after
PCI to a concentration of >0.04ng/mL. We further divided PMI
into 2 groups. If cTnI increase<5URL, it was considered a PMI
of low degree, whereas an increase to ≥ 5was considered a PMI
of high degree (Table 1). If basal cTnI was >URL, then an
increase of >20% of basal value was considered a PMI of high
degree, and an increase of< 20% of basal value was considered a
PMI of low degree (Table 1).
This classiﬁcation and cut-off values were derived from the
most recent ESC Consensus document on myocardial infarc-
tion.[7]
Patients were divided into 2 groups according to the eGFR. The
control group comprised of patients with eGFR ≥90mL/min/
1.73 m2 and in the CKD group there were patients with eGFR
< 90mL/min/1.73 m2. The CKD group was further subdivided
into 4 groups depending on the CKD stage: (1) eGFR 60 to 89mL/
min/1.73 m2, (2) eGFR 30 to 59mL/min/1.73 m2, (3) eGFR 15 to
29mL/min/1.73m2, (4) eGFR<15mL/min/1.73m2.Wehave used
CKD classiﬁcation based on 5 categories of eGFR proposed by the
Kidney Disease Outcomes Quality Initiative (KDOQI).[8,9]
GFR was calculated using the Modiﬁcation of Diet in Renal
Disease (MDRD) study 4 variable equation: estimated glomeru-
lar ﬁltration rate=186.3 (serum standardized creatinine mg/
dL)1.154age0.203 (0.742 if female) (1.21 if black).[10]
We also tested association of baseline demographic, clinical,
angiographic and procedural characteristics with the incidence of
PMI. Hypertension was deﬁned as blood pressure >160/90 mm
Hg on repeat measurements, or current use of antihypertensive
medications. Hyperlipidemia was deﬁned as documented
hyperlipidemia or use of lipid-lowering medications. Smoking
status was deﬁned as current smoking or having quit within 6
months before PCI. Coronary lesions were classiﬁed according to
the American College of Cardiology/American Heart Association
(ACC/AHA) into 3 groups (types A, B, C) based on angiographic
ﬁndings.[11]
The primary end point was the incidence of PMI at 8 or 16
hours after elective stent implantation in the control and the CKD
groups.2.1. Statistical analysis
Numerical data are presented as mean±SD in the case of
continuous variables with normal distribution, or as median with
IQR in the case of not normal distribution. The difference
between 2 groups in continuous variables was tested with
Student’s t-test in normally distributed variables or withcTnI after 8 h (ng/mL) cTnI after 16 h (ng/mL)
<URL <URL
URL<cTnI<5URL URL<cTnI<5URL
cTnI ≥ 5URL cTnI ≥ 5URL
Rise of cTnI < 20% Rise of cTnI < 20%
Rise of cTnI > 20% Rise of cTnI > 20%
L).
Table 2
Baseline characteristics of the study participants.
eGFR
>90 mL/min/
1.73 m2 (n=128)
eGFR
<90 mL/min/
1.73 m2 (n=216) P
Male, n, % 102 (79.6) 140 (64.8) 0.003
Age, y 59.7±8.1 67.1±10.2 <0.001
BMI >30 kg/m2, % 38 (29.6) 73 (33.7) 0.43
Hypertension, n, % 112 (87.5) 201 (93.0) 0.08
Hyperlipidemia, % 107 (83.6) 186 (86.1) 0.64
Diabetes mellitus, n, % 38 (29.6) 83 (38.4) 0.10
Jerkic et al. Medicine (2016) 95:45 www.md-journal.comMann–Whitney’s U test in non-normally distributed variables.
The difference between 2 groups in categorical variables was
tested with Pearson’s chi-squared test. A multivariate logistic
regression analysis was performed to determine variables
independently associated with PMI. All variables that
were associated with respective outcome in bivariate analysis
(at P 0.1) were included in the multivariate regression.
Statistical signiﬁcance was considered at P value <0.05. All
statistical analyses were performed by using Statistica for
Windows 12.0 software (Statsoft, Tulsa, OK).Current smoker, n, % 37 (28.9) 33 (15.3) 0.002
Previous PCI, n, % 43 (33.6) 65 (30.1) 0.50
Previous CABG, n, % 3 (2.3) 9 (4.1) 0.37
Medication:
ACE inhibitors, n, % 107 (83.6) 188 (87.1) 0.47
ARB, n, % 11 (8.6) 22 (10.2) 0.62
Beta blockers, n, % 110 (85.9) 177 (81.9) 0.50
Lipid-lowering drugs, n, % 106 (82.8) 188 (87.1) 0.23
ACE= angiotensin-converting enzyme, ARB= angiotensin II receptor blocker, BMI=body mass index,
CABG= coronary artery bypass grafting, eGFR= estimated glomerular ﬁltration rate, PCI=
percutaneous coronary intervention.3. Results
We enrolled 344 patients, among which 242 (70.3%) were males
and 102 (29.7%) were females.
There were 128 (37.2%) patients in the control group with
eGFR≥90mL/min/1.73m2 and 216 (62.8%) patients in the CKD
group with eGFR <90mL/min/1.73 m2. In the CKD group 136
(39.5%) patients had eGFR 60 to 89mL/min/1.73 m2, 52
(15.1%) patients had eGFR 30 to 59mL/min/1.73 m2, 6 (1.8%)
patients were with eGFR 15 to 29mL/min/1.73m2 and 22 (6.4%)
patients with eGFR <15mL/min/1.73 m2 (Fig. 1).
Patients in the CKD group were older, more likely to be male
and less likely to be current smokers. Other characteristics were
similar in the 2 groups. Baseline characteristics for the total study
population are given in Table 2.
Angiographic and procedural characteristics in both groups
were similar. There were no signiﬁcant differences in lesion
locations, type of lesions (AHA/ACC type), and stent procedures
between control and study groups. Lesion and procedural
characteristics are given in Table 3.
cTnI in the control and the CKD groups increased 8 and 16
hours after PCI (Fig. 2). However, rise in cTnI was similar in CKD
and control groups (Fig. 2).
Among all patients, the incidence of PMI of high degree 8hours
after elective PCI was 16.5% (57 patients) and 16hours afterFigure 1. Distribution of patients according to the eGFR (mL/min/1.73m2).
eGFR=estimated glomerular ﬁltration rate.
3elective PCI was 31.7% (109 patients). The incidence of PMI of
low degree 8hours after PCI was 29.4% (101 patients) and 16
hours after PCI 31.1% (107 patients) (Fig. 3).
There were no signiﬁcant differences in the incidence of PMI of
low or high degree 8 and 16hours after PCI in patients with CKD
and in those without CKD. The incidence of PMI of low degree 8
hours after PCI in the control group was 29.6% (38 patients) and
in the CKD group 29.2% (63 patients). On the other hand, 16
hours after PCI a PMI of low degree occurred in 31.2% (40
patients) in the control group and in 31.1% (67 patients) in the
CKD group. The incidence of PMI of high degree 8hours after
PCI in the control group was 17.9% (23 patients) and in the CKDTable 3
Lesion and procedural characteristics.
GFR >90 mL/min/
1.73m2 (n=128)
GFR <90 mL/min/
1.73m2 (n=216) P
Left main disease, n, % 0 (0) 3 (1.4) 0.18
Left anterior descending
coronary artery, n, %
35 (27.4) 73 (33.8) 0.21
Circumﬂex coronary artery, n, % 25 (19.5) 40 (18.5) 0.82
Right coronary artery, n, % 44 (34.3) 72 (33.3) 0.84
AHA/ACC type:
A, n, % 54 (42.2) 77 (35.6) 0.22
B, n, % 49 (38.3) 95 (44.0) 0.30
C, n, % 24 (18.7) 46 (21.3) 0.57
Bare-metal stent, n, % 75 (58.6) 129 (59.8) 0.86
Drug-eluting stent, n, % 36 (28.1) 66 (30.5) 0.64
Direct stenting, n, % 33 (25.8) 48 (22.2) 0.56
Maximum dilatation
pressure, atm
15.9±4.1 16.4±3.3 0.15
Total stent length, mm 17.8±6.7 18.5±6.4 0.32
Total stent diameter, mm 2.8±0.85 2.9±0.76 0.74
Contrast agent, iodixanol/
ioversol; %/%
83.6/16.4 83.8/16.2 0.96
Contrast volume per
procedure, mL
179.8±80.1 179.4±82.3 0.96
AHA/ACC=American Heart Association/ American College of Cardiology, GFR=glomerular ﬁltration
rate.
Figure 2. cTnI changes after PCI in the control and CKD groups. CKD=
chronic kidney disease, cTnI=cardiac troponin I, PCI=percutaneous coronary
intervention.
Figure 4. Incidence of PMI 8h after PCI in patients with CKD and patients
without CKD. CKD=chronic kidney disease, eGFR=estimated glomerular
ﬁltration rate, PCI=percutaneous coronary intervention, PMI=periprocedural
myocardial injury.
Jerkic et al. Medicine (2016) 95:45 Medicinegroup 15.7% (34 patients). High degree PMI 16hours after PCI
occurred in 33.6% (43 patients) in the control group and 30.6%
(66 patients) in the CKD group (Figs. 4 and 5).
We further assessed incidence and severity of PMI with respectto CKD burden (i.e., CKD stage). We found no signiﬁcant
differences in the incidence of PMI of high or low degree 8 and 16
hours after PCI in groups according to the eGFR.
The incidence of PMI of low degree 8hours after PCI in the
CKD group with eGFR 60–89mL/min/1.73 m2 was 28.7% (39
patients) and high degree PMI occurred in 16.9% (23 patients)
The incidence of PMI of low degree in the CKD group with eGFR
30–59mL/min/1.73 m2 was 28.8% (15 patients) and the
incidence of high degree PMI was 15.4% (8 patients). In the
group with eGFR 15–29mL/min/1.73 m2, the incidence of PMI
of low degree was 33.3% (2 patients) and PMI of high degreeFigure 3. Incidence of PMI among all the patients. eGFR=estimated glomerular
myocardial injury.
4occurred in 33.3% (2 patients). Lastly, in the group with eGFR
<15mL/min/1.73 m2, the incidence of PMI of low degree was
31.8% (7 patients) and high degree 4.5% (1 patient) (Fig. 6).
The incidence of a PMI of low degree 16hours after PCI in
CKD group with eGFR 60–89mL/min/1.73 m2 was 30.2% (41
patients) and a PMI of high degree was 32.3% (44 patients). The
incidence of PMI of low degree in CKD group with eGFR 30–59
mL/min/1.73 m2 was 38.5% (20 patients) and a PMI of high
degree occurred in 21.2% (11 patients). In the group with eGFR
15–29mL/min/1.73 m2, the incidence of PMI of low degree was
16.7% (1 patients) and high degree was seen in 50.0% (3
patients). And in the group with GFR <15mL/min/1.73 m2, the
incidence of PMI of low degree was 22.7% (5 patients), whereas
high degree PMI occurred in 36.4% (8 patients) (Fig. 7).
Patients with eGFR <15mL/min/1.73 m2 had signiﬁcantly
higher levels of C-reactive protein (CRP) before PCI as well as 8ﬁltration rate, PCI=percutaneous coronary intervention, PMI=periprocedural
Figure 5. Incidence of PMI 16h after PCI in patients with CKD and patients without CKD. CKD=chronic kidney disease, eGFR=estimated glomerular ﬁltration rate,
PCI=percutaneous coronary intervention, PMI=periprocedural myocardial injury.
Jerkic et al. Medicine (2016) 95:45 www.md-journal.comand 16hours after PCI compared to the control group (Table 4).
However, we found no signiﬁcant differences in CRP levels
between control and other CKD groups.
To further evaluate possible inﬂuence of other clinical factors
on our results, we conducted further statistical analyses. In
univariate analyses, predictors of any type of PMI, that is, both of
low degree and of high degree, were: smoking history (P=0.02),
previous IM (P=0.007), treatment with ACEI (P=0.001),
angina pectoris CCS grade IV (P=0.001), multivessel CAD
(P=0.01), BMS (P=0.001), stent diameter (P=0.02), and basal
cTnI (P=0.008). In univariate analyses, we have also found some
variables associated with reduced risk of any type of PMI:
treatment with beta blockers (P=0.05), DES (drug-eluting stent,
P=0.004), hypertension (P=0.01), and 1 vessel CAD (P=
0.007).
In a multiple logistic regression model, angina pectoris CCS
grade IV, ACEI therapy and BMS remained signiﬁcant indepen-
dent risk factors for PMI after elective PCI (OR 2.159, 95% CI
1.168–3.989, P=0.01, OR 8.725, 95% CI 2.700–28.194, P=Figure 6. Incidence of PMI 8h after PCI according to the eGFR. eGFR=
estimated glomerular ﬁltration rate, PCI=percutaneous coronary intervention,
PMI=periprocedural myocardial injury.
50.0002 and OR 2.184, 95% CI 1.199–3.980, P=0.01), whereas
hypertension remained an independent protective factor for
the development of PMI (OR 0.289, 95% CI 0.116–0.717,
P=0.007) (Table 5).4. Discussion
Previous studies have shown that a cTn elevation after elective
PCI suggests myocardial injury that is related to an increase in the
risk of subsequent MI and death.[12] According to the available
evidence, baseline cTn elevation in stable coronary disease, is
associated with worse long-term prognosis and late cardiovascu-
lar mortality.[13] Postprocedural cTn elevation with normal
baseline value is associated not only with the late mortality but
also with in-hospital mortality.[14] According to those ﬁndings,
present guidelines recommend routine measurement of cardiac
biomarkers both before and after PCI in order to identify high-
risk patients.[7] Multiple studies, addressing this issue, have
shown the relation between PMI and prognosis, but there were aFigure 7. Incidence of PMI 16h after PCI according to the eGFR. eGFR=
estimated glomerular ﬁltration rate, PCI=percutaneous coronary intervention,
PMI=periprocedural myocardial injury.
Table 5
Independent predictors and protective factors for the periproce-
duralm myocardial injury after elective percutaneous coronary
intervention.
Predictors OR 95% CI P
ACE inhibitors 8.725 2.700–28.194 <0.001
Angina pectoris CCS grade IV 2.159 1.168–3.989 0.01
BMS 2.184 1.199–3.980 0.01
Hypertension 0.289 0.116–0.717 0.007
ACE inhibitors= angiotensin-converting enzyme inhibitors, BMS=bare metal stent, CCS=Canadian
Cardiovascular Society, CI= conﬁdence interval, OR= odds ratio.
Table 4
C-reactive protein in patients with glomerular ﬁltration rate <15
mL/min/1.73 m2 compared to the control group.
GFR (mL/min/1.73m2) ≥ 90 < 15 P
Baseline CRP, mg/mL 5.10±10.7 15.95±25.70 0.001
CRP 8 h after PCI 4.93±12.48 17.36±29.77 <0.001
CRP 16 h after PCI 6.67±14.50 20.37±34.25 0.003
CRP=C-reactive protein, GFR=glomerular ﬁltration rate, PCI = percutaneous coronary intervention.
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that were used. Such a divergence of deﬁnitions, that were used in
previous studies, has forced key opinion leaders and cardiology
associations to deﬁne periprocedural injury. The deﬁnition that
was brought has been evolving in the past 2 decades. Historically,
the deﬁnition of periprocedural MI was any rise of cTn over the
URL, and there was no difference between PMI and periproce-
dural MI.[15] The deﬁnition from 2007 used cTn elevation
≥3URL as a periprocedural MI and <3URL was deﬁned as
PMI.[16] According to the latest deﬁnition endorsed by the ESC,
ACCF, AHA, and the WHF, which was used in our study, all
patients with postprocedural cTn rise of <5URL were deﬁned
as having a PMI of lower degree. A rise of ≥5URL, in the
absence of ischemic, angiographic or imaging ﬁndings, was
deﬁned as a PMI of a higher degree. Another group of patients
that we included, again in accordance with the latest deﬁnition,
included stable patients with elevated basal cTn values, which
were stable or falling. In such patients, PMI of lower degree is
deﬁned as any rise of cTn <20% after PCI. Rise of ≥20% is
deﬁned as a PMI of higher degree. A separate, distinct group of
patients is the group with unsuccessful procedure or an
angiographic complication that leads to the postprocedural
ECG or echocardiographic changes. Those patients are deﬁned
by the above deﬁnition as having a PCI-related MI (type 4a),[7]
and those patients were excluded from our study. We believe that
such a periprocedural injury is almost exclusively related to the
procedural technique and should be addressed from the technical
standpoint rather than trying to explain such an injury by
patient’s baseline characteristics.
The main ﬁnding of our study was that CKD is not a risk factor
for occurrence of PMI.We did not ﬁnd that any level of CKDwas
associated with higher incidence of PMI (either higher or lower
degree), despite the fact that CKD is an important cardiovascular
risk factor.[17] This is especially interesting, when knowing that
some previous observations have shown that CKD patients had
worse outcomes after coronary revascularization.[18] Extensive
investigation of the relationship between CKD and PMI after
elective PCI was done by Kumagai et al[18] It was found that
patients with CKD deﬁned as GFR <60mL/min/1.73 m2 had a
higher incidence of PMI compared to patients with GFR > 60
mL/min/1.73 m2. In that study, GFR was estimated using a
formula that was speciﬁcally designed for the Japanese popula-
tion.[18,19] Although an explanation for discrepant results
between the present and the Kumagai study is not entirely clear,
there are some important methodology differences in relation to
PMI deﬁnition and study subject inclusion between the 2studies.
In the Kumagai report, deﬁnition of PMI that was used
(>3URL) was derived from the deﬁnition that was contempo-
rary at that moment.[16] Hence, it is not in the accordance with
the current recommendations for the PMI diagnosis. Also, it is
not clear whether patients with elevated basal cTnT were
included and if they were, in what way was the inclusion done. In6addition, mathematical manipulation with the baseline levels of
cTnT that was done could have inﬂuenced the observed incidence
of PMI, while by including only the patients with a rise in cTnT to
>3 URL, they might have missed those with milder forms of
PMI. On the other hand, these patients with mild PMI were
included in our study. All those issues may have resulted in the
underestimation of PMI occurrence in the Kumagai study, which
might have led to the differences in the results of our 2 groups. In
addition, we strongly believe that patients with mild PMI should
always be included in such studies, as it was shown that even so-
called troponin microleaks inﬂuence the prognosis after PCI.[20]
Limitation of our study was relatively small sample size of
stages 4 and 5 CKD patients, so further analysis comprising a
larger number of advanced CKD patients is needed to verify our
results.
We also found that patients with end-stage CKD had
signiﬁcantly higher levels of inﬂammation marker CRP before
PCI and 8 and 16hours after PCI compared to patients with
preserved GFR. New evidence suggest that inﬂammation is the
most important mechanism of accelerated coronary calciﬁcation
and endothelial dysfunction in CKD.[21] Thus, CRP should not be
observed as a mere inﬂammation marker, but it can also serve as
an indicator of increased cardiovascular morbidity in hemodial-
ysis patients.
By doing further statistical analyses, we tried to ﬁnd other
possible clinical factors that could be associated with the
occurrence of PMI. From the previous studies, it is known that
aspirin, clopidogrel, beta-blockers, and statins may reduce PMI
and patients scheduled for PCI should be pretreated with these
drugs.[22] Beneﬁts of statin treatment can be explained not only
by their lipid-lowering potential, but also by pleiotropic effects
that modify endothelial function, inﬂammation responses, plaque
stability, and thrombus formation.[23] Two randomized trials
have analyzed the role of intracoronary beta-blocker propranolol
during PCI and showed that propranolol signiﬁcantly reduced
CK-MB, TnT, and clinical end points at 30 days post-PCI.[24]
Retrospective studies have shown that intracoronary calcium
antagonists nicardipine and verapamil have been successfully
used in the treatment of no-reﬂow following PCI but have failed
to reduce the incidence of PMI.[25] Schaefer and group of authors
have shown, in a small number of patients, that intracoronary
ACEIs during primary PCI suppress reperfusion-associated
ventricular arrhythmias and improve coronary blood ﬂow.[26]
One recent study showed that chronic therapy with ACEI prior to
elective PCI is associated with a 64% relative risk reduction of
procedural MI.[27] Unfortunately, the limitations of that study
were baseline inequalities between study groups. In our study,
quite oppositely, we found that ACEI therapy was associated
with an increased incidence of PMI. This is, however, unlikely to
be the effect of ACE inhibition itself, but it might reﬂect some
Jerkic et al. Medicine (2016) 95:45 www.md-journal.comassociated clinical characteristics. For example, we found that
patients on chronic ACEI had higher baseline prevalence of
adverse prognostic features including diabetes, hypertension,
previous MI and previous PCI, or CABG (data not shown). In
addition, there are several studies that have warned of episodes of
profound hypotension during surgical procedures in patients
treated chronically with ACEI.[28] Such hypotensive episodesmay
have lead to coronary hypoperfusion and myocardial injury
during PCI. This would further be in agreement with our ﬁnding
that, in a multivariate logistic regression analysis, hypertension is
inversely related to the development of PMI.
Furthermore, we found that BMS implantation signiﬁcantly
increased the incidence of PMI after elective PCI, arguing for use
of DES in order to avoid PMI. Looking solely at the CKD
patients, there may be several reasons to use DES instead of BMS.
Shenoy et al[29] have shown in their study of 436 CKD patients,
that use of DES in CKD was safe and effective in the long term,
with lower risk of all-cause death, target vessel revascularization
(TVR), and the composite of major adverse cardiovascular events
(MACE) and similar risk of MI and stent thrombosis (ST) as
compared to BMS. Patients with CKD, especially end-stage renal
disease, have higher in-stent restenosis rates, and that may be the
reason of absolute beneﬁt of DES compared to BMS, knowing
that DES signiﬁcantly suppressed neointimal hyperplasia and
reduced the risk of restenosis compared to BMS.[30,31] Unfortu-
nately, there are no large prospective randomized studies
comparing DES with BMS regarding the incidence of PMI in
both CKD as well as in non-CKD patients. Our ﬁnding that BMS
is associated with signiﬁcantly higher incidence of PMI may be
explained by higher inﬂammatory reaction after BMS implanta-
tion. BMS implantation is associated with higher risk of in stent
restenosis and the crucial mechanism for that is inﬂammation.[32]
On the other side, inﬂammation plays an important role in the
pathogenesis of PMI. Bonz et al[33] have shown that inﬂamma-
tory markers are elevated in patients with PMI. So, 1 might
speculate that BMS implantation in our patients was associated
with higher incidence of PMI because of exaggerated inﬂamma-
tory reaction.
We have also found angina pectoris CCS grade IV as a
signiﬁcant and independent risk factor in the development of
PMI. Broda et al[34] have shown, on 300 patients with coronary
artery disease, that more extensive coronary lesions correspond
to more severe coronary symptoms. They have found that there
was signiﬁcant correlation between coronary symptoms severity
(CCS) and anatomic lesions revealed by angiography. Conse-
quently, our ﬁnding may reﬂect more complex underlying
coronary anatomy in CCS grade IV patients, which resulted in
higher occurrence of PMI.
At the end, we have shown that despite the pharmacologic and
technical advances and greater experience with stenting techni-
ques, the incidence of PMI after elective PCI is still quite high.With
this regard, our results are similar to the results of the other study
groups.[35,36] Large prospective trials showed that post-PCI
elevation of cTn (>5 URL), deﬁned in our study as PMI of
higher degree, is clinically relevant and has prognostic implications
similar to those of spontaneous acute myocardial infarction.[37,38]
More recent studies suggested that the degree of cardiovascular
risk correlates with the extent of rise of cTn and imaging studies
demonstrated that post-procedural levels of cTn represent new
irreversible myocardial injury.[39] Additional studies are needed to
address strategies to reduce the risk for PMI after PCI.
Another important issue in patients with CKD, that was not
subject of the present study, is contrast-induced nephropathy7(CIN). Patients with CKD are at increased risk of developing CIN
after coronary intervention procedures. Before these procedures,
patients should be assessed for risk of CIN using a simple clinical
ACEF risk score as a predictor of acute kidney injury after
PCI.[40] European Society of Cardiology (ESC) Guidelines
recommended that all patients with moderate to severe CKD
should receive preventive hydration with isotonic saline, to be
started ∼12hours before angiography and continued for at least
24hours afterward to reduce the risk of CIN. The guidelines also
recommend application of low-osmolar or iso-osmolar contrast
media and volume of contrast media should be minimized. The
contrast volume should be maintained <4mL/kg or <350 mL in
1 procedure. Use of high-dose statin before coronary angiogra-
phy, should be also considered as an additional preventive
measure and in patients with severe CKD, ESC Guidelines
recommended prophylactic hemoﬁltration 6hours before PCI.[41]
In our study, we have used in all patients low osmolar contrast
media (iodixanol or ioversol), aiming to minimize risk for CIN
with all patients being hydrated prior to procedure with isotonic
saline, as well.[42]
However, we cannot report on the incidence of CIN in the
present report, because majority of patients had been discharged
from the hospital within 24hours following the angiography.5. Conclusion
We found no association between PMI occurrence and the
presence of CKD. Furthermore, CKD burden (i.e., stratiﬁcation
of patients according to the CKD stage) was also not associated
with higher PMI incidence. But, future studies comprising a larger
number of advanced CKD patients are needed to verify these
ﬁndings and further address the issue of both PMI diagnosis and
its prognostic implication in patients with CKD.References
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